Drug Information

Drug General Information
Drug ID
D0S9SQ
Former ID
DIB016754
Drug Name
JCAR015
Indication B-cell lymphoma [ICD9: 202.8; ICD10:C85.1] Phase 2 [525305]
Company
Juno therapeutics
Target and Pathway
Target(s) B-lymphocyte antigen CD19 Target Info Modulator [551860]
KEGG Pathway PI3K-Akt signaling pathway
Hematopoietic cell lineage
B cell receptor signaling pathway
Epstein-Barr virus infection
Primary immunodeficiency
NetPath Pathway IL-7 Signaling Pathway
PANTHER Pathway B cell activation
Pathway Interaction Database BCR signaling pathway
Reactome PIP3 activates AKT signaling
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Constitutive Signaling by Aberrant PI3K in Cancer
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Human Complement System
Signaling by the B Cell Receptor (BCR)
PIP3 activates AKT signaling
B Cell Receptor Signaling Pathway
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 525305ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL).
Ref 551860Clinical pipeline report, company report or official report of JUNO Therapeutics.